Study of Azacitidine and Durvalumab in Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Microsatellite Stable Colorectal Carcinoma|Platinum Resistant Epithelial Ovarian Cancer Type II|Estrogen Receptor Positive and HER2 Negative Breast Cancer
Interventions: DRUG: Azacitidine|DRUG: Durvalumab
Sponsor: University Health Network, Toronto